There is a good news in Wuxi Further Pharmaceutical Company. Avanafil API puts on records in NMPA. The record was authorized. The DMF number is Y20220000202, the BE number is 202200210-01, which was occurred on 14th March 2022. It means that Wuxi Further can export this API to foreign countries. At the same time, the quality of Avanafil is up to international standard, and conforms to export requirement.

Avanafil (Zepeed) was approved by the Korean Health Ministry for the treatment of erectile dysfunction (ED) in August 2011. Avanafil is a highly selective type 5 phosphodiesterase (PDE5) inhibitor. Avanafil is reported to be the most selective PDE5 inhibitor on the market. The onset of Tmax and half-life also varies among the marketed PDE5 inhibitors. Sildenafil has a Tmax at 1 h and a half-life of 3–5 h. Vardenafil is somewhat similar with a Tmax of 0.6 h and a half-life of 4–6 h. Tadalafil has the longest half-life among the marketed drugs with a half-life of 17 h. Avanafil has a fast onset of action reaching Tmax in 0.6 h with a half-life of 1.2 h. A synthesis of avanafil (TA-1790) is described in the patent literature. The main elimination route of avanafil is through the bile and feces. Avanafil was also found to be reabsorbed through enterohepatic recirculation.

In addition, Avanafil is a highly selective PDE5 inhibitor with IC50 of 1 nm, which is a phosphodiesterase (PDE5) inhibitor, used to treat erectile dysfunction.